Drug intelligence / Profile preview

xg-104

Development stage: Phase 2
Lead developer: Xigen
Modality: Peptides
Administration: Ophthalmic

Overview

XG-104 is a synthetic peptide drug developed by Xigen for the treatment of eye diseases, specifically dry eye syndromes and xerophthalmia. Its mechanism of action is as an inhibitor of c-Jun N-terminal kinase (JNK), also known as JNK mitogen-activated protein kinase. By inhibiting JNK, XG-104 targets pathways involved in inflammation and cellular stress responses that contribute to ocular surface disease. The drug has reached Phase 2 clinical trials for dry eye syndromes but has not been approved or marketed in any country.

Targets

JNK (Mitogen-activated protein kinase kinase kinase family)

Beyond the preview

Go deeper on xg-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xg-104.

Explore the full profile